P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival

Abstract

The treatment landscape for patients with metastatic non-small cell lung cancer with a MET exon 14 skipping mutation (MET ex14) is rapidly changing, with recent approvals of MET selective tyrosine kinase inhibitors (TKIs) and reports of durable response to immune checkpoint inhibitors (ICI). Currently there are no published data that inform the sequencing of TKIs and ICI regimens. We sought to characterize treatment patterns and sequencing outcomes at 3 Ontario cancer centres.